【佳學基因檢測】生物學觀點

基因檢測大約多少錢比較分析

數(shù)據(jù)分析獲悉《Rev Mal Respir》在?1998 Jun;15(3 Pt 2):428-40發(fā)表了一篇題目為《生物學觀點》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由J L Pujol,?P Demoly,?X Quantin,?J Simony,?E Parrat,?M Lehmann,?J P Daurès,?G Jolimoy,?J Grenier,?B Pau,?P Godard等完成。促進了腫瘤的正確治療與個性化用藥的發(fā)展，進一步強調了基因信息檢測與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究內容關鍵詞：

0

腫瘤靶向治療基因檢測臨床應用結果

非小細胞支氣管癌的腫瘤生物學整合了賊近的發(fā)展和腫瘤進展和轉移性疾病擴散現(xiàn)象的動態(tài)模式。在第二階段和第三階段之間沒有已知的生物破壞。后者由解剖學標準定義，是這些癌癥自然史連續(xù)體的過渡。腫瘤進展的動力是基因型不穩(wěn)定性和表型多樣化。轉移性顯微鏡下疾病是 III 期非小細胞支氣管癌治療失敗的首要原因。在生存的預后因素中，重點放在 p53 表達的改變、不同類型的非整倍體、細胞粘附分子表達的異常以及賊后，腫瘤向轉移表型的多樣化。

腫瘤發(fā)生與反復轉移國際數(shù)據(jù)庫描述：

The tumour biology of non-small cell bronchial cancer integrates recent developments and a dynamic schema of the phenomena of tumour progression and diffusion of the metastatic disease. There is no leap of known biological disruption between Stage II and Stage III. The latter is defined by anatomical criteria and is a transition in the continuum of the natural history of these cancers. The moto for the tumour progression is the genotypic instability and phenotypic diversification. Metastatic microscopic disease constitutes the first cause of failure in the treatment of Stage III non-small cell bronchial cancer. Among prognostic factors for survival emphasis is placed on the alterations of p53 expression, different types of aneuploidy, anomalies of the expression of cellular adhesion molecules and finally, tumour diversification towards a metastatic phenotype.